

# NEWSLETTER

Issue 22 | September 2022

## Issue 22

**Headlines: EAS FHSC dedicates this issue to Dr. Mario Stoll**

**FHSC Global Network and Registry**

[findmylipidclinic.com](http://findmylipidclinic.com)

**FHSC National Lead Investigators' Reports**

**FH Studies Collaboration**

c/o EAS Office

Tel: +46(0)31 760 24 27

Fax: +46(0)31 81 20 22

[info@eas-fhsc.org](mailto:info@eas-fhsc.org)

Follow us:

[#fhscglobalregistry](https://twitter.com/fhscglobalregistry)

## FHSC dedicates this issue to Dr. Mario Stoll



**Dr. Mario Stoll (1950-2022).**

We received sad news of the death of our retired FHSC National Lead Investigator of Uruguay Dr. Mario Stoll. Dr. Stoll was known personally to many within the global community and his achievements and substantial contributions will continue to prosper.

Prof. Raul Santos (FHSC Executive Committee and National Lead Investigator of Brazil) says:


*"We all have the pleasant memory of his (Dr. Stoll) presence at the recent meeting of the Ibero-American Network (IB) of Familial Hypercholesterolemia (FH), in which he conveyed to us, once again, his unwavering desire to continue promoting the Network as an integrating project of a common objective that is the improvement of the quality of life of people with FH".*

Dr. Stoll developed his career in Montevideo, Uruguay, then spent some time as a molecular biologist at Yale University, USA. Later he incorporated these Molecular Genetics tools in the cardiology practice of Uruguay. Dr. Stoll was the Director of the GENYCO Programme (Genes and Cholesterol) of Uruguay that has contributed to the development of an organisation of FH patients and genetic screening sanctioned by the parliament of Uruguay in 2012. He has also been the secretary and founder of the FH IB Network.

*"His legacy transcends borders in the area of Ibero-American countries."*

- Says Prof. Raul.

The EAS FHSC now spans 74 countries (shaded map) and includes 87 Lead Investigators; specifically the National Lead Investigators are listed [here](#). EAS FHSC Registry includes 69,334 cases across 66 countries thus far.



## Become part of the expanding EAS FHSC

Do you have an interest in FH, collect clinical and/or genetic FH data and are keen to contribute to the **EAS FHSC Global Registry** ([CT.gov Identifier: NCT04272697](#))?

If so, we would like to hear from you!  
For enquires contact [info@eas-fhsc.org](mailto:info@eas-fhsc.org)

**More information about the EAS FHSC can be found in these publications:**

- [FHSC Study Protocol: 'Pooling and expanding registries of FH'](#)
- [FHSC Survey: 'Overview of the current status of FH care in over 60 countries'](#)
- [FHSC Results: 'A global perspective on FH: Cross-sectional study from the EAS FHSC'](#)

**FHSC Coordinating Centre** provides a free essential web-based resource exclusive to FHSC Investigators and their local teams to support entering and managing local-level data, and sharing data with the FHSC Global Registry. Ask the Coordinating Centre for more details.

## ‘FindMyLipidClinic.com: A global Directory of lipid clinics and patient organisations to improve dyslipidemia care’

The recently established *European Heart Journal* has published the article above, which is freely-available online: [Stevens et al. EAJ 2022;2:37-40](#)

This article promotes [findmylipidclinic.com](https://findmylipidclinic.com) by explaining its unique features and global spread of clinics and patient organisations that benefits individuals and their families living with dyslipidaemias using this global directory.

Both the FHSC and FH Europe have contributed to populating this directory.

### HELP THIS INITIATIVE GROW ...

We urge lipid specialists to register their clinics and for dyslipidaemia patient support groups to register their organisations in [findmylipidclinic.com](https://findmylipidclinic.com) (follow link).

Please share findmylipidclinic.com amongst your clinical and patient networks to help make good use of this global directory.

Please share this [EHJ article](#)

## The first FH Symposium in Tanzania

On Tuesday 6<sup>th</sup> December we arranged the first FH symposium at Muhimbili National Hospital in Dar es Salaam, Tanzania. We discussed the importance of early diagnosis and proper treatment of this genetic lipid disorder to help reduce risks associated with FH and the importance of disseminating knowledge amongst both healthcare professionals and the public about this disorder. This event will be followed by the establishment of the first lipid clinic in Tanzania. We are expressing our deep gratitude to Prof. Mohammed Janabi, CEO of the hospital, for the kind support to make the event possible and successful.



## The first FH symposium in Djibouti

As part of our international campaign to increase awareness of FH in the African horn region, the Iraqi Lipid Clinics Network arranged in collaboration with colleagues at the Community Health Centre 7 in Djibouti the first FH symposium for resident doctors and general practitioners working there to discuss the impact of this genetic lipid disorder. We discussed all related issues of this disorder (prevalence, cardiovascular consequences, skin manifestations, the importance of early detection and treatment and the important strategies we designed to control its burden in the community. We are extremely grateful to our colleague (Salwa Baqi from Morocco) for her pivotal role in making this event successful.



**Dr. Mutaz Alkhnifsawi**  
National Lead Investigator of Iraq